Brittany Weber1,2, Katherine P Liao3, Marcelo DiCarli1,2, Ron Blankstein1,2. 1. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3. Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Patients with chronic inflammatory disease have an increased risk of cardiovascular disease. This article reviews the current evidence of cardiovascular prevention in three common systemic inflammatory disorders (SIDs): psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. RECENT FINDINGS: General population cardiovascular risk assessment tools currently underestimate cardiovascular risk and disease-specific risk assessment tools are an area of active investigation. A disease-specific cardiovascular risk estimator has not been shown to more accurately predict risk compared with the current guidelines. Rheumatoid arthritis-specific risk estimators have been shown to better predict cardiovascular risk in some cohorts and not others. Systemic lupus erythematosus-specific scores have also been proposed and require further validation, whereas psoriasis is an open area of active investigation. The current role of universal prevention treatment with statin therapy in patients with SID remains unclear. Aggressive risk factor modification and control of disease activity are important interventions to reduce cardiovascular risk. SUMMARY: A comprehensive approach that includes cardiovascular risk factor modification, control of systemic inflammation, and increased patient and physician awareness is needed in cardiovascular prevention of chronic inflammation. Clinical trials are currently underway to test whether disease-specific anti-inflammatory therapies will reduce cardiovascular risk.
PURPOSE OF REVIEW: Patients with chronic inflammatory disease have an increased risk of cardiovascular disease. This article reviews the current evidence of cardiovascular prevention in three common systemic inflammatory disorders (SIDs): psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. RECENT FINDINGS: General population cardiovascular risk assessment tools currently underestimate cardiovascular risk and disease-specific risk assessment tools are an area of active investigation. A disease-specific cardiovascular risk estimator has not been shown to more accurately predict risk compared with the current guidelines. Rheumatoid arthritis-specific risk estimators have been shown to better predict cardiovascular risk in some cohorts and not others. Systemic lupus erythematosus-specific scores have also been proposed and require further validation, whereas psoriasis is an open area of active investigation. The current role of universal prevention treatment with statin therapy in patients with SID remains unclear. Aggressive risk factor modification and control of disease activity are important interventions to reduce cardiovascular risk. SUMMARY: A comprehensive approach that includes cardiovascular risk factor modification, control of systemic inflammation, and increased patient and physician awareness is needed in cardiovascular prevention of chronic inflammation. Clinical trials are currently underway to test whether disease-specific anti-inflammatory therapies will reduce cardiovascular risk.
Authors: Jon T Giles; Naveed Sattar; Sherine Gabriel; Paul M Ridker; Steffen Gay; Charles Warne; David Musselman; Laura Brockwell; Emma Shittu; Micki Klearman; Thomas R Fleming Journal: Arthritis Rheumatol Date: 2020-01 Impact factor: 10.995
Authors: P Coto-Segura; N Eiris-Salvado; L González-Lara; R Queiro-Silva; P Martinez-Camblor; C Maldonado-Seral; B García-García; L Palacios-García; S Gomez-Bernal; J Santos-Juanes; E Coto Journal: Br J Dermatol Date: 2013-10 Impact factor: 9.302
Authors: George D Kitas; Peter Nightingale; Jane Armitage; Naveed Sattar; Jill J F Belch; Deborah P M Symmons Journal: Arthritis Rheumatol Date: 2019-07-22 Impact factor: 10.995
Authors: Michele Colaci; Luca Zanoli; Alberto Lo Gullo; Domenico Sambataro; Gianluca Sambataro; Maria Letizia Aprile; Pietro Castellino; Lorenzo Malatino Journal: J Clin Med Date: 2022-06-07 Impact factor: 4.964